Vigilant Raises $5M to Commercialize Oral Cancer Test

July 11, 2016

Vigilant Biosciences has raised $5 million to commercialize OncAlert, its oral cancer detection test.

Vigilant has received $12.5 million in total funding, including most recently a round of $5 million in Series B funding. The proceeds will be used for the international commercialization of OncAlert and to continue the company’s research and development efforts.

Source: DrBicuspid

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev2